The FDA has requested Eli Lilly conduct additional long-term safety studies for its newly approved oral obesity drug Foundayo, specifically flagging risks like heart attack, stroke, and liver injury. The demand for more data on Lilly's next-generation obesity treatment intensifies regulatory scrutiny. The conditional approval, granted on April 1, requires Eli Lilly to provide further evidence regarding Foundayo's long-term safety and tolerability.
Eli Lilly's new oral obesity drug Foundayo was approved by the FDA and demonstrated significant weight loss. However, the agency is demanding further long-term safety studies due to concerns about serious adverse events. This decision creates tension between immediate patient access and the need for exhaustive safety data.
Despite promising efficacy, the market rollout and widespread adoption of oral obesity drugs like Foundayo will likely face extended scrutiny and potential delays as regulators prioritize long-term patient safety.
Foundayo's Efficacy: Significant Weight Loss Demonstrated
- The primary endpoint, a statistically significant reduction in body weight from baseline to week 36 compared with placebo, was met across all aleniglipron doses, according to Nature.
- The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was -9.0% for 45 mg, -10.7% for 90 mg, and -12.1% for 120 mg compared with placebo (-0.8%), as reported by oral small molecule glp-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
- Similar percentages of participants completed the study treatment in the aleniglipron arms (73.3% to 78.1%) and the pooled placebo group (75.0%), Nature states.
